Daniel Kim to Melanoma
This is a "connection" page, showing publications Daniel Kim has written about Melanoma.
Connection Strength
4.390
-
Kim DY, Behbahani S, Moncayo A, Trepanowski N, Hartman RI. Disparities in melanoma presentation and overall survival among disaggregated Hispanic nationalities: A retrospective analysis of 2,517 patients in the National Cancer Database. Arch Dermatol Res. 2024 Jun 08; 316(7):377.
Score: 0.708
-
Kim DY, Dee EC, Cheng I, Hartman RI. Advanced melanoma presentation and disease-specific survival disparities among disaggregated Asian American, Native Hawaiian, and Pacific Islander populations. J Am Acad Dermatol. 2024 03; 90(3):623-626.
Score: 0.680
-
Kim DY, Swetter SM, Huhmann L, Dizon MP, Ferguson JM, Osborne TF, Spence AC, Ziad A, Fillmore N, Hartman RI. Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma. J Am Acad Dermatol. 2024 03; 90(3):620-623.
Score: 0.680
-
Kim DY, Hartman RI. Incidence of In Situ and Invasive Cutaneous Melanomas During the COVID-19 Pandemic in the US. JAMA Dermatol. 2023 10 01; 159(10):1141-1145.
Score: 0.676
-
Kim DY, Marchetti MA, Hartman RI. Differences in thickness-specific incidence of cutaneous melanoma by county type in the United States, 2010 to 2019. J Am Acad Dermatol. 2023 09; 89(3):597-600.
Score: 0.658
-
Kim DY, Behbahani S, Hartman RI. Impact of COVID-19 pandemic on melanoma presentation by facility type and region in the United States. J Am Acad Dermatol. 2023 07; 89(1):175-178.
Score: 0.650
-
Pan CX, Liu M, Lau CB, Lau WC, Kim DY, Saberi SA, Rowley R, Kanwar R, Giobbie-Hurder A, LeBoeuf NR, Nambudiri VE. Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors. J Am Acad Dermatol. 2024 04; 90(4):826-829.
Score: 0.171
-
Pan CX, Lau WC, Kim DY, Lau CB, Rowley R, Kanwar R, LeBoeuf NR, Nambudiri VE. Association between baseline lactate dehydrogenase and immune-related adverse events among patients with melanoma varies by tumor stage at immune checkpoint inhibitor initiation. J Am Acad Dermatol. 2023 12; 89(6):1264-1268.
Score: 0.167